DSP aims to extend Japan repaglinide use through new filing
This article was originally published in Scrip
Dainippon Sumitomo Pharma (DSP) is looking to broaden the use of its antidiabetic Surepost (repaglinide; licensed from Novo Nordisk) in Japan through an approval filing for use in combination with either biguanide or thiazolidinedione drugs.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.